Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Taft

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Pharmacokinetics|February 9, 2021
Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumptionVamshi Krishna Jogiraju, Tycho Heimbach, Yuliana Toderika, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 12, 2011
Renal excretion of apricitabine in rats: ex vivo and in vivo studiesMariana Babayeva, Susan Cox, Michael P White, et al.
The Journal of Pharmacy and Pharmacology|June 7, 2013
Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposureMichael P White, Mariana Babayeva, David R Taft, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2003
Characterization of pentamidine excretion in the isolated perfused rat kidneyNagaraju R Poola, Michelle Kalis, Fotios M Plakogiannis, et al.
Journal of Clinical Pharmacology|May 4, 2021
Application of Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial EffectHarshith Neeli, Nazeeh Hanna, Khaled Abduljalil, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2009
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agentAmy W Chun, Stephen C Cosenza, David R Taft, et al.
Drug Development and Industrial Pharmacy|February 23, 2010
Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney modelMitalee Tamhane, Ananthsrinivas R Chakilam, Andrew Jayaraj, et al.
Pharmaceutics|April 28, 2023
Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug AlbendazoleHarsh Shah, Kushal Shah, Bhavin Gajera, et al.
Journal of Pharmaceutical Sciences|December 6, 2012
Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposureMitalee Tamhane, Manoj Maniar, Chen Ren, et al.
International Journal of Pharmaceutics|March 22, 2005
Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitroMohammed A Kabir, David R Taft, Cecil K Joseph, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Pharmacokinetics|February 9, 2021
Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumptionVamshi Krishna Jogiraju, Tycho Heimbach, Yuliana Toderika, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 12, 2011
Renal excretion of apricitabine in rats: ex vivo and in vivo studiesMariana Babayeva, Susan Cox, Michael P White, et al.
The Journal of Pharmacy and Pharmacology|June 7, 2013
Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposureMichael P White, Mariana Babayeva, David R Taft, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2003
Characterization of pentamidine excretion in the isolated perfused rat kidneyNagaraju R Poola, Michelle Kalis, Fotios M Plakogiannis, et al.
Journal of Clinical Pharmacology|May 4, 2021
Application of Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial EffectHarshith Neeli, Nazeeh Hanna, Khaled Abduljalil, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2009
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agentAmy W Chun, Stephen C Cosenza, David R Taft, et al.
Drug Development and Industrial Pharmacy|February 23, 2010
Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney modelMitalee Tamhane, Ananthsrinivas R Chakilam, Andrew Jayaraj, et al.
Pharmaceutics|April 28, 2023
Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug AlbendazoleHarsh Shah, Kushal Shah, Bhavin Gajera, et al.
Journal of Pharmaceutical Sciences|December 6, 2012
Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposureMitalee Tamhane, Manoj Maniar, Chen Ren, et al.
International Journal of Pharmaceutics|March 22, 2005
Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitroMohammed A Kabir, David R Taft, Cecil K Joseph, et al.
Pageof 3